4.4 Article

High endoplasmic reticulum activity renders multiple myeloma cells hypersensitive to mitochondrial inhibitors

期刊

CANCER CHEMOTHERAPY AND PHARMACOLOGY
卷 66, 期 1, 页码 129-140

出版社

SPRINGER
DOI: 10.1007/s00280-009-1143-1

关键词

Multiple myeloma; Mitochondria; Fenofibrate; Troglitazone; Calcium; Unfolded protein response

资金

  1. NCI [CA37109]

向作者/读者索取更多资源

Multiple myeloma (MM) cells continuously secrete large amounts of immunoglobulins that are folded in the endoplasmic reticulum (ER) whose function depend on the Ca2+ concentration inside its lumen. Recently, it was shown that the ER membrane leaks Ca2+ that is captured and delivered back by mitochondria in order to prevent its loss. Thus, we hypothesized that the highly active and abundant ER in MM cells results in greater Ca2+-regulation by mitochondria which would render them sensitive to mitochondrial inhibitors. Here, we indeed find that Ca2+ leak is greater in 3 MM, when compared to 2 B-cell leukemia cell lines. Moreover, this greater leak in MM cells is associated with hypersensitivity to various mitochondrial inhibitors, including CCCP. Consistent with our hypothesis, CCCP is more potent in inducing the unfolded protein response marker, CHOP/GADD153 in MM versus B-cell leukemia lines. Additionally, MM cells are found to be significantly more sensitive to clinically used fenofibrate and troglitazone, both of which were recently shown to have inhibitory effects on mitochondrial function. Overall, our results demonstrate that the unusually high ER activity in MM cells may be exploited for therapeutic benefit through the use of mitochondrial inhibitors including troglitazone and fenofibrate.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Review Oncology

Immunotherapy in Multiple Myeloma: Accelerating on the Path to the Patient

Irene Ghobrial, Calixto Hernandez Cruz, Alfred Garfall, Nina Shah, Nikhil Munshi, Jonathan Kaufman, Lawrence H. Boise, Gareth Morgan, Viktor A. Adalsteinsson, Salomon Manier, Rathi Pillai, Fabio Malavasi, Sagar Lonial

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2019)

Article Multidisciplinary Sciences

Multiple myeloma immunoglobulin lambda translocations portend poor prognosis

Benjamin G. Barwick, Paola Neri, Nizar J. Bahlis, Ajay K. Nooka, Madhav Dhodapkar, David L. Jaye, Craig C. Hofmeister, Jonathan L. Kaufman, Vikas A. Gupta, Daniel Auclair, Jonathan J. Keats, Sagar Lonial, Paula M. Vertino, Lawrence H. Boise

NATURE COMMUNICATIONS (2019)

Review Immunology

Cell of Origin and Genetic Alterations in the Pathogenesis of Multiple Myeloma

Benjamin G. Barwick, Vikas A. Gupta, Paula M. Vertino, Lawrence H. Boise

FRONTIERS IN IMMUNOLOGY (2019)

Article Multidisciplinary Sciences

Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma

Richa Bajpai, Aditi Sharma, Abhinav Achreja, Claudia L. Edgar, Changyong Wei, Arusha A. Siddiqa, Vikas A. Gupta, Shannon M. Matulis, Samuel K. McBrayer, Anjali Mittal, Manali Rupji, Benjamin G. Barwick, Sagar Lonial, Ajay K. Nooka, Lawrence H. Boise, Deepak Nagrath, Mala Shanmugam

NATURE COMMUNICATIONS (2020)

Article Oncology

Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma

Nisha S. Joseph, Jonathan L. Kaufman, Madhav Dhodapkar, Craig C. Hofmeister, Dhwani K. Almaula, Leonard T. Heffner, Vikas A. Gupta, Lawrence H. Boise, Sagar Lonial, Ajay K. Nooka

JOURNAL OF CLINICAL ONCOLOGY (2020)

Letter Oncology

Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents

Roberto Mina, Nisha S. Joseph, Francesca Gay, Efstathios Kastritis, Maria Teresa Petrucci, Jonathan L. Kaufman, Vittorio Montefusco, Maria Gavriatopoulou, Francesca Patriarca, Paola Omede, Lawrence H. Boise, Maria Roussou, Nicola Giuliani, Stefania Oliva, Massimo Offidani, Angelo Belotti, David L. Jaye, Lorenzo De Paoli, Evangelos Terpos, Sagar Lonial, Mario Boccadoro, Ajay K. Nooka, Meletios A. Dimopoulos

BLOOD CANCER JOURNAL (2020)

Article Cell Biology

CD28 Regulates Metabolic Fitness for Long-Lived Plasma Cell Survival

Adam Utley, Colin Chavel, Shivana Lightman, G. Aaron Holling, James Cooper, Peng Peng, Wensheng Liu, Benjamin G. Barwick, Catherine M. Gavile, Orla Maguire, Megan Murray-Dupuis, Cheryl Rozanski, Martha S. Jordan, Taku Kambayashi, Scott H. Olejniczak, Lawrence H. Boise, Kelvin P. Lee

CELL REPORTS (2020)

Review Oncology

Keeping Myeloma in Check: The Past, Present and Future of Immunotherapy in Multiple Myeloma

James Ackley, Miguel Armenta Ochoa, Delta Ghoshal, Krishnendu Roy, Sagar Lonial, Lawrence H. Boise

Summary: Multiple myeloma is an incurable disease characterized by malignant plasma cells, making it a prime target for modern immune therapy. Immune therapy for multiple myeloma can be categorized into IMiDs, targeted antibodies, adoptive cell transfer therapies, and vaccines, all showing advancements in improving antitumor activity and specificity.

CANCERS (2021)

Editorial Material Hematology

Agent myeloma has a new weapon from (ch1)Q

Timothy M. Schmidt, Lawrence H. Boise

Summary: In this study, the authors use multiomics analysis to identify a novel transcriptional network that is crucial for the poor outcomes associated with chromosome 1q amplification in multiple myeloma.
Article Oncology

PDZ Proteins SCRIB and DLG1 Regulate Myeloma Cell Surface CD86 Expression, Growth, and Survival

Tyler Moser-Katz, Catherine M. Gavile, Benjamin G. Barwick, Kelvin P. Lee, Lawrence H. Boise

Summary: Despite advances in multiple myeloma treatment, the disease remains incurable. This study reveals the role of CD86 cytoplasmic tail in trafficking CD86 to the cell surface and identifies SCRIB and DLG1 as important proteins for myeloma cell growth and survival.

MOLECULAR CANCER RESEARCH (2022)

Article Oncology

Multivariant Transcriptome Analysis Identifies Modules and Hub Genes Associated with Poor Outcomes in Newly Diagnosed Multiple Myeloma Patients

Olayinka O. Adebayo, Eric B. Dammer, Courtney D. Dill, Adeyinka O. Adebayo, Saheed O. Oseni, Ti'ara L. Griffen, Adaugo Q. Ohandjo, Fengxia Yan, Sanjay Jain, Benjamin G. Barwick, Rajesh Singh, Lawrence H. Boise, James W. Lillard

Summary: This study investigates the molecular mechanisms underlying treatment failures in multiple myeloma using bioinformatic tools. Through gene co-expression network analysis, modules of genes associated with disease survival status were identified and crucial genes within these modules were further studied. The findings reveal the biological functions related to the risk of death in multiple myeloma, providing insights for improving treatment strategies for the disease.

CANCERS (2022)

Article Medicine, Research & Experimental

TGF-β causes Docetaxel resistance in Prostate Cancer via the induction of Bcl-2 by acetylated KLF5 and Protein Stabilization

Yixiang Li, Baotong Zhang, Lingwei Xiang, Siyuan Xia, Omer Kucuk, Xingming Deng, Lawrence H. Boise, Jin-Tang Dong

THERANOSTICS (2020)

Article Hematology

Integrated phosphoproteomics and transcriptional classifiers reveal hidden RAS signaling dynamics in multiple myeloma

Yu-Hsiu T. Lin, Gregory P. Way, Benjamin G. Barwick, Margarette C. Mariano, Makeba Marcoulis, Ian D. Ferguson, Christoph Driessen, Lawrence H. Boise, Casey S. Greene, Arun P. Wiita

BLOOD ADVANCES (2019)

Article Medicine, Research & Experimental

Early alterations in stem-like/marrow-resident T cells and innate and myeloid cells in preneoplastic gammopathy

Jithendra Kini Bailur, Samuel S. McCachren, Deon B. Doxie, Mahesh Shrestha, Katherine Pendleton, Ajay K. Nooka, Natalia Neparidze, Terri L. Parker, Noffar Bar, Jonathan L. Kaufman, Craig C. Hofmeister, Lawrence H. Boise, Sagar Lonial, Melissa L. Kemp, Kavita M. Dhodapkar, Madhav Dhodapkar

JCI INSIGHT (2019)

Article Cell Biology

The prodomain of caspase-3 regulates its own removal and caspase activation

Katelyn G. Ponder, Lawrence H. Boise

CELL DEATH DISCOVERY (2019)

暂无数据